Study Critical Of Chinese Biotech Medicine Not Subject To Trials (China)
This article was originally published in PharmAsia News
Executive Summary
A study of a sector of medical biotechnology practiced in China is critical of some of the drugs, stem cell and other genetic therapy being produced and performed without regulatory oversight. One of the authors said the approach being used by Beike Biotechnologies and other firms in China would mark them as "rogue companies" in the Western world. The study published in Nature Biotechnology said treatments are attracting foreigners desperate for cures even though no clinical trials have authenticated their efficacy because the State Food and Drug Administration does not require them. (Click here for more
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.